Skip to content
Prof. Dr. Mustafa Özdoğan · Medical Oncologist

CRISPR/CAS9 Sets Its Sights on Replacing Immunotherapies in Cancer Treatment

CRISPR/CAS9 Sets Its Sights on Replacing Immunotherapies in Cancer Treatment

Considered one of the century's most important discoveries, CRISPR/CAS9 technology holds great promise for treating solid (organ) tumors as well as genetic diseases. Cancer arises from thousands of epigenetic and genetic abnormalities. At the same time, the tumor microenvironment supports cancer cell growth. Recently developed CAR-T cell therapies also aim to enable T cells to recognize and attack cancer cells.

You May Be Interested:

The figure below explains how CRISPR can be used in cancer immunotherapy. T cells taken from the patient are genetically modified with crispr. The PD-1 gene is inactivated. As a result, the PD-1 protein that deactivates T cells cannot be produced, and immune cells become able to attack cancer cells. The activated T cells are returned to the patient, creating an effective cancer treatment.

crispr cas9 and T-cell therapy advances in cancer immunotherapy

Are There Clinical Studies of CRISPR-CAS9 in Cancer Immunotherapy?

There are 7 ongoing clinical studies on using CRISPR in cancer treatment. Information about the clinical studies is available in the table below.

CRISPR Cas9 Clinical Trials in Solid Organ Cancers

All these studies suggest that CRISPR may perhaps replace immune checkpoint inhibitors , the new generation of effective immunotherapies that are currently very costly.

Sources

Chen Patricia , You Liting , and Lu You.
Applications of CRISPR-Cas9 Technology in Translational Research on Solid-Tumor Cancers.
The CRISPR Journal, Feb 2018.

Appointment request

DROZDOGAN AI

Explore this article together

Ask about the article and read answers alongside published sources from our site.

DROZDOGAN AI

Drozdogan Assistant

CRISPR/CAS9 Sets Its Sights on Replacing Immunotherapies in Cancer Treatment

Ask about the article and read answers alongside published sources from our site.

Conversation and privacy information

Drozdogan Assistant answers this conversation. Authorized site administrators may review it for quality. Do not share personal information.

Replies use OpenAI infrastructure. Questions and replies are processed by that service; conversation records are stored on our site. Do not share identifying, contact or personal health information.

0 / 1000

For information only; no personal diagnosis or treatment advice.

Related articles

Explore other articles on this topic.

Stay informed

Receive new articles and scientific updates by email.

Google Analytics runs on public pages independently of this window and may use analytics cookies. Your choice here controls external services only.

Cookie policy